Introduction
Cancer therapies are currently more efficient at increasing the survival of patients (pts) with cancer. Unfortunately, the cardiovascular (CV) complications of cancer therapies may adversely affect improving results of treatment. The aim of the study was to evaluate the prevalence of classical CV risk factors among pts with de novo diagnosis of cancer and thus identify the cohort of pts with potentially increased future risk of CV complications.

Material and methods
The analysis is based on the database of the multicentre ONCOECHO study. Pts before systemic treatment (chemotherapy or targeted therapy) were included. The diagnostic datasets of resting electrocardiogram, blood samples, and transthoracic echocardiogram were analysed in 343 consecutive pts who were free from any cardiovascular disease that could adversely affect the introduced treatment.

Results
Our cohort included 4.4% of pts with kidney cancer, 7.3% with colorectal cancer, 26.5% with haematological malignancies (HM), and 61.8% with breast cancer. The risk estimated by SCORE was 4.56 ±5.07%. Breast cancer pts had lower cardiovascular risk than those with HM (p = 0.001) and kidney cancer (p = 0.002). Additionally, the HM group had much higher levels of natriuretic peptides (p < 0.001) and creatinine (p = 0.008) than pts with breast cancer. The comparison with the NATPOL population data showed that our pts were more often smokers, hypertensives, and diabetics, but less frequently presented with hypercholesterolaemia.

Conclusions
Patients with new diagnosis of cancer, who are candidates for potentially cardiotoxic medical treatment, have increased prevalence of significant cardiovascular risk factors and therefore should be followed by a multidisciplinary team during the therapeutic process.



中文翻译：

---

符合全身治疗条件的癌症患者的心血管危险因素。来自波兰多中心研究 ONCOECHO 的无心血管疾病队列分析

简介
癌症疗法目前在提高癌症患者 (pts) 的存活率方面更为有效。不幸的是，癌症治疗的心血管 (CV) 并发症可能会对改善治疗结果产生不利影响。该研究的目的是评估新诊断癌症患者中经典心血管危险因素的患病率，从而确定未来心血管并发症风险可能增加的患者队列。

材料与方法
该分析基于多中心 ONCOECHO 研究的数据库。纳入全身治疗（化疗或靶向治疗）前的患者。连续分析了 343 名患者的静息心电图、血液样本和经胸超声心动图的诊断数据集，这些患者没有任何可能对引入的治疗产生不利影响的心血管疾病。

结果
我们的队列包括 4.4% 的肾癌患者、7.3% 的结直肠癌患者、26.5% 的血液系统恶性肿瘤 (HM) 患者和 61.8% 的乳腺癌患者。SCORE 估计的风险为 4.56 ±5.07%。乳腺癌患者的心血管风险低于 HM（p = 0.001）和肾癌患者（p = 0.002）。此外，与乳腺癌患者相比，HM 组的利钠肽 (p < 0.001) 和肌酐 (p = 0.008) 水平要高得多。与 NATPOL 人群数据的比较表明，我们的患者更多是吸烟者、高血压患者和糖尿病患者，但较少出现高胆固醇血症。

结论
新诊断的癌症患者是潜在心脏毒性药物治疗的候选者，其显着心血管危险因素的患病率增加，因此在治疗过程中应由多学科团队跟进。